SCHAUMBURG, Ill. (AP) - Biotechnology company Abraxis BioScience Inc. said
its hospital business Abraxis Pharmaceutical Products received tentative Food
and Drug Administration approval for generic Kytril.
The injectible drug is made by Hoffmann-La Roche and treats side effects
from cancer therapy including nausea and vomiting. Roche's patent is set to
expire either Dec. 29. or June 28, if the company receives pediatric exclusivity
for the drug.
Barr Pharmaceuticals Inc. has also received tentative approval for a generic
version of the drug.
Shares of Abraxis closed at $21.73 Monday.
Copyright 2007 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten, or redistributed.
|